Markers of prognosis and response to treatment: Ready for clinical use in oncology? A biostatistician's viewpoint

International Journal of Biological Markers

Volumn 18, Issue 1, 2003, Pages 65-69

  Boracchi, Patrizia ^a   Biganzoli, E ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; PLASMINOGEN ACTIVATOR INHIBITOR 1; TAMOXIFEN; TRASTUZUMAB; TUMOR MARKER; UROKINASE; VASCULOTROPIN;

BIOSTATISTICS; CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER SCREENING; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; DIAGNOSTIC VALUE; DISEASE MARKER; DRUG RESPONSE; HEALTH CARE COST; HIGH RISK PATIENT; HUMAN; ONCOGENE NEU; PREDICTION; PROGNOSIS; QUALITY OF LIFE; STATISTICAL ANALYSIS;

EID: 0142155633     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.5301/JBM.2008.5242     Document Type: Conference Paper

References (24)

1. Hayes DF, Bast RC, Desch CE, et al. Tumor marker utility grading system: A framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 1456-66.
2. Hayes DF, Trock B, Harris AL. Assessing the clinical impact of prognostic factors: When is "statistically significant" clinically useful? Breast Cancer Res Treat 1998; 52: 305-19.
3. Altman DG. Systematic reviews of evaluations of prognostic variables. BMJ 2001; 323: 224-8.
4. Gion M, Boracchi P, Biganzoli E, Daidone MG. A guide for reviewing submitted manuscripts (and indications for the design of translational research studies on biomarkers). Int J Biol Markers 1999; 14: 123-33.
5. Altman DG, Lausen B, Sauerbrei W, Schumacher M. Dangers of using "optimal" cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst 1994; 86: 829-35.
6. Sargent D, Allegra C. Issues in clinical trial design for tumor marker studies. Semin Oncol 2002; 29: 222-30.
7. Galea MH, Blamey RW, Elston CE, Ellis IO. The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat 1992; 22: 207-19.
8. Cooke T, Reeves J, Lannigan A, Stanton P. The value of the human epidermal growth factor receptor-2 (HER2) as a prognostic marker. Eur J Cancer 2001; 37 (suppl 1): 3-10.
9. Coradini D, Boracchi P, Daidone MG, et al. Contribution of vascular endothelial growth factor to the Nottingham prognostic index in node-negative breast cancer. Br J Cancer 2001; 85: 795-7.
10. Hansen S, Grabau DA, Sorensen FB, Bak M, Vach W, Rose C. Vascular grading of angiogenesis: Prognostic significance in breast cancer. Br J Cancer 2000; 82: 339-47.
11. Hayes DF, Thor AD. c-erbB-2 in breast cancer: Development of a clinically useful marker. Semin Oncol 2002; 29: 231-45.
12. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Senn H-J. Meeting highlights: International consensus panel on the treatment of primary breast cancer. J Clin Oncol 2001; 19: 3817-27.
13. Mansour EG, Gray R, Shatila AH, et al. Survival advantage of adjuvant chemotherapy in high-risk node-negative breast cancer: Ten-year analysis - An intergroup study. J Clin Oncol 1998; 16: 3486-92.
14. Harbeck N, Kates RE, Schmitt M. Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination. J Clin Oncol 2002; 20: 1000-7.
15. Lockwood CA, Ricciardelli C, Raymond WA, Seshadri R, McCaul K, Horsfall DJ. A simple index using video image analysis to predict disease outcome in primary breast cancer. Int J Cancer 1999; 84: 203-8.
16. Altman DG, Royston P. What do we mean by validating a prognostic model? Stat Med 2000; 19: 453-73.
17. Ravdin PM. Is Her2 of value in identifying patients who particularly benefit from anthracyclines during adjuvant therapy? A qualified yes. J Natl Cancer Inst Monogr 2001; 80-4.
18. Sledge GW, Jr. Is HER-2/neu a predictor of anthracycline utility? No. J Natl Cancer Inst Monogr 2001; 85-7.
19. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20: 719-26.
20. Eiermann W. Trastuzumab combined with chemotherapy for the treatment of HER2-positive metastatic breast cancer: Pivotal trial data. Ann Oncol 2001; 12: 57-62.
21. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpress HER2. N Engl J Med 2001; 344: 783-92.
22. Amadori D, Nanni O, Marangolo M, et al. Disease-free survival advantage of adjuvant cyclophosphamide, methotrexate, and fluorouracil in patients with node-negative, rapidly proliferating breast cancer: A randomized multicenter study. J Clin Oncol 2000; 18: 3125-34.
23. Paradiso A, Schittulli F, Cellamare G, et al. Randomized clinical trial of adjuvant fluorouracil, epirubicin, and cyclophosphamide chemotherapy for patients with fast-proliferating, node-negative breast cancer. J Clin Oncol 2001; 19: 3929-31.
24. Janicke F, Prechtl A, Thomssen C, et al. Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and and plasminogen activator inhibitor type 1. J Natl Cancer Inst 2001; 93: 913-20.